semaglutide gastroparesis lawsuit in michigan Ozempic, Mounjaro manufacturers sued over claims of "stomach paralysis" side effects semaglutide gastroparesis class action in

The mice were sacrificed on days 0, 5, 10, 20, and 30 after the start of HFD feeding and then liver tissues were collected

(2023) 165(4):e15874

My fitness journey inspired my mission to live a longer, healthier, more vibrant life

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy